Organogenesis Holdings ((ORGO)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Study Overview: Organogenesis Holdings is conducting a study titled A Multicenter, Prospective, Randomized Controlled Modified Platform Trial Assessing the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers. The study aims to evaluate the effectiveness of a new treatment for chronic diabetic foot ulcers, a significant health issue affecting many individuals with diabetes.
Intervention/Treatment: The study tests two interventions: PuraPly AM and PuraPly XT, both of which are antimicrobial wound matrices designed to enhance healing when used alongside standard care practices.
Study Design: This interventional study is randomized with a parallel assignment model. There is no masking involved, and the primary purpose is treatment. Participants are allocated to receive either the standard care alone or in combination with one of the two PuraPly treatments.
Study Timeline: The study began on September 26, 2024, with the latest update submitted on April 2, 2025. These dates are crucial as they indicate the study’s progression and ongoing recruitment status.
Market Implications: The successful outcome of this study could positively impact Organogenesis Holdings’ stock performance by demonstrating the efficacy of their new treatments. This could also influence investor sentiment positively, especially in comparison to competitors in the wound care market.
The study is currently ongoing, and further details can be accessed on the ClinicalTrials portal.